Skip to content
Research Article Open access CC BY 3.0

Rock Inhibitors: Future of Anti-glaucoma Medication

Vishal Vohra, Harshika Chawla, Malvika Gupta

Ophthalmology Research: An International Journal · pp. 361–367 · Published 8 Jul 2014

10.9734/OR/2014/10573

Abstract

Glaucoma constitutes the major burden of irreversible blindness worldwide as of today. All the modalities of treatment are focussed on lowering intraocular pressure (IOP), from medical to surgical. With the advent of new drugs, drug compliance has increased among the patients but still is the most worrisome problem for doctors. Current research is focussed to treat glaucoma by means other than just lowering IOP. Among the various molecules under trial, one group is Rho kinaseinhibitors (ROCK INHIBITORS). They modulate cellular motility of the trabecular meshwork, schlemm’s canal, and ciliary muscle, thereby enhancing aqueous drainage. Being still under trials, hopes are on that these could revolutionise glaucoma therapy.  

Rho kinase inhibitors ROCK inhibitors glaucoma trabecular meshwork remodeling

References (25)

  1. 1 ROCKs: multifunctional kinases in cell behaviour [DOI]
  2. 2 The small GTP‐binding protein Rho binds to and activates a 160 kDa Ser/Thr protein kinase homologous to myotonic dystrophy kinase. [DOI]
  3. 3 Aqueous Humor in Glaucomatous Eyes Contains an Increased Level of TGF-β2 [DOI]
  4. 4 Actomyosin-Mediated Cellular Tension Drives Increased Tissue Stiffness and β-Catenin Activation to Induce Epidermal Hyperplasia and Tumor Growth [DOI]
  5. 5 Modulation of aqueous humor outflow facility by the Rho kinase-specific inhibitor Y-27632.
  6. 6 An Assessment of the Health and Economic Burdens of Glaucoma [DOI]
  7. 7 Effects of rho-associated protein kinase inhibitor Y-27632 on intraocular pressure and outflow facility.
  8. 8 Blood flow in glaucoma [DOI]
  9. 9 The ROCK Inhibitor Eye Drop Accelerates Corneal Endothelium Wound Healing [DOI]
  10. 10 Barriers to adherence with glaucoma medications: a qualitative research study [DOI]
  11. 11 Rho GTPase/Rho Kinase Inhibition as a Novel Target for the Treatment of Glaucoma [DOI]
  12. 12 Application of Rho Antagonist to Neuronal Cell Bodies Promotes Neurite Growth in Compartmented Cultures and Regeneration of Retinal Ganglion Cell Axons in the Optic Nerve of Adult Rats [DOI]
  13. 13 Rho-kinase inhibitors as therapeutics: from pan inhibition to isoform selectivity [DOI]
  14. 14 The role of the actomyosin system in regulating trabecular fluid outflow [DOI]
  15. 15 The Glaucoma Research Community and FDA Look to the Future: A Report from the NEI/FDA CDER Glaucoma Clinical Trial Design and Endpoints Symposium * [DOI]
  16. 16 Endothelin-like immunoreactivity in aqueous humor of patients with primary open-angle glaucoma and cataract [DOI]
  17. 17 Contribution of ROCK in Contraction of Trabecular Meshwork: Proposed Mechanism for Regulating Aqueous Outflow in Monkey and Human Eyes [DOI]
  18. 18 Involvement of RhoA and possible neuroprotective effect of fasudil, a Rho kinase inhibitor, in NMDA-induced neurotoxicity in the rat retina [DOI]
  19. 19 Evidence for Protein Kinase C-Mediated Activation of Rho- Kinase in a Porcine Model of Coronary Artery Spasm [DOI]
  20. 20 Pharmacological management of ocular hypertension: current approaches and future prospective [DOI]
  21. 21 Vasospasm in Glaucoma: Clinical and Laboratory Aspects [DOI]
  22. 22 Enhanced survival and regeneration of axotomized retinal neurons by repeated delivery of cell-permeable C3-like Rho antagonists [DOI]
  23. 23 Therapeutic efficacy of azaindole-1 in experimental pulmonary hypertension [DOI]
  24. 24 Evidence That Estrogen Suppresses Rho-Kinase Function in the Cerebral Circulation In Vivo [DOI]
  25. 25 The Effect of Rho-Associated Kinase Inhibition on the Ocular Penetration of Timolol Maleate [DOI]

Cited by 6

Rho-kinase (ROCK) Inhibitors - A Neuroprotective Therapeutic Paradigm with a Focus on Ocular Utility

Vasudha Abbhi, Poonam Piplani · Current Medicinal Chemistry · 2020

Showing 1 of 6 known citations — external sources report more than can currently be individually listed.

Article metrics

Real usage data collected on this platform.

26

Page views

0

PDF downloads

9

Outbound clicks

6

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.